A social gradient in fatal opioids and cocaine related overdoses?

PLoS One. 2015 May 4;10(5):e0125568. doi: 10.1371/journal.pone.0125568. eCollection 2015.
Date de parution
mai 2015
Type
Article
Editeur
Plos One
Auteur
Alain ORIGER, Etienne LE BIHAN, Michèle BAUMANN
A social gradient in fatal opioids and cocaine related overdoses?
Langue: Anglais
pdf, 173 Ko

BACKGROUND:
To determine the existence of a social gradient in fatal overdose cases related to non-prescribed opioids and cocaine use, recorded in Luxembourg between 1994 and 2011.
METHODS:
Overdose cases were individually matched with four controls in a nested case-control study design, according to sex, year of birth, drug administration route and duration of drug use. The study sample, composed of 272 cases and 1,056 controls, was stratified according to a Social Inequality Accumulation Score (SIAS), based on educational attainment, employment, income, financial situation of subjects and the professional status of their father or legal guardian. Least squares linear regression analysis on overdose mortality rates and ridit scores were applied to determine the Relative Index of Inequality (RII) of the study sample.
RESULTS:
A negative linear relationship between the overdose mortality rate and the relative socioeconomic position was observed. We found a difference in mortality of 29.22 overdose deaths per 100 drug users in the lowest socioeconomic group compared to the most advantaged group. In terms of the Relative Inequality Index, the overdose mortality rate of opioid and cocaine users with lowest socioeconomic profiles was 9.88 times as high as that of their peers from the highest socioeconomic group (95% CI 6.49-13.26).
CONCLUSIONS:
Our findings suggest the existence of a marked social gradient in opioids and cocaine related overdose fatalities. Harm reduction services should integrate socially supportive offers, not only because of their general aim of social (re)integration but crucially in order to meet their most important objective, that is to reduce drug-related mortality.

Souce: Pubmed

  • Dernière modification le 10-11-2015